STOCKHOLM, January 26 /PRNewswire/ -- Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
In studies to date, Eribis' novel peptide therapy has shown excellent Cardio-protective effects in conditions of ACS and reperfusion. Potential benefits of the candidate drug include a decrease in the amount of cardiac tissue damage, an extension of the window of time available for treatment of ischemic conditions and a reduction of cardiovascular complications such as heart failure.
Eribis Pharmaceutical's CEO, Herman Krapf, said, "We are delighted that Karolinska Development continues to show confidence in our development program. This latest round of financing comes after strong preclinical results and means we can now move forward towards the clinical program. Successful development offers significant market potential as there is an urgent need for new and improved therapies in the area of cardio-protection."
About Acute Coronary Syndrome
Cardiovascular disorders are the leading cause of mortality worldwide and
remain an area of unmet medical needs. Acute coronary syndrome (ACS) refers
to any group of clinical symptoms compatible with acute myocardial ischaemia
(chest pain due to insufficient blood supply to the
|SOURCE Eribis Pharmaceuticals AB|
Copyright©2010 PR Newswire.
All rights reserved